Medical Technology Breaking News: Aethlon Medical (OTC: AEMD,
AEMDD) Discloses Presentation of Preliminary CTE Related Study Results
SAN DIEGO - April 16, 2015 (Investorideas.com newswire)
Aethlon Medical, Inc. (OTCQB: AEMD, AEMDD), a pioneer in developing targeted therapeutic
devices to address infectious diseases and cancer, announced today that Dr.
Robert Stern, professor of neurology, neurosurgery, and anatomy and
neurobiology at Boston University School of Medicine (BUSM) has presented
preliminary, unpublished findings related to research being conducted by
Aethlon Medical's majority owned subsidiary, Exosome Sciences, Inc. The
presentation was given earlier today at the 5th Annual Traumatic Brain Injury
Conference being held in Washington, D.C.
The
findings are part of the Diagnosing and Evaluating Traumatic Encephalopathy
using Clinical Tests (DETECT) study, a research project funded by the National
Institutes of Health (NIH), being conducted at BUSM's CTE Program. The DETECT
study examines potential biomarkers for CTE by studying a sample of former
professional American football players and a control group of same-age men
without any history of brain trauma from contact sport involvement. In
connection with the DETECT study, researchers at Exosome Sciences have been
applying proprietary techniques to isolate microscopic exosomes that transport
CTE associated tau protein (tausomes) across the blood brain barrier.
As
part of the DETECT project at BUSM, blood samples from 78 former NFL players
and 16 control subjects were analyzed by Exosome Sciences researchers. In the
study, researchers were able to isolate and quantify the presence of tausomes
in the blood. During his presentation, Dr. Stern reported that former NFL
players' tausome levels were measured to be significantly higher than those of
the control subjects. Moreover, in the former NFL player group, tausome levels
also significantly correlated with performance on formal memory tests; the
higher the tausome level, the worse the memory performance. In contrast,
previous cerebrospinal fluid measurements of tau and phosphorylated tau in the
same subjects were not significantly correlated with memory test performance.
The results presented by Dr. Stern are preliminary and additional testing will
be required.
Read this release
in full at http://www.investorideas.com/CO/AEMD/news/2015/04161.asp
About Chronic traumatic
encephalopathy (CTE)
CTE
is a neurodegenerative disease associated with a history of repetitive brain
trauma, often seen in former contact sport athletes, such as boxers and
American football players, as well as in military service members. Symptoms of
CTE include memory impairment, behavior change (including impulsivity), and
mood disturbance (including depression and suicidality), with advanced cases
demonstrating dementia. At present, the diagnosis of CTE can only be made
through postmortem examination of brain tissue, which demonstrates a unique
pattern of deposition of an abnormal form of a protein called tau.
About Aethlon Medical, Inc.
Aethlon
Medical creates medical devices that target unmet therapeutic needs in
infectious disease and cancer. The company's lead product is the Aethlon
Hemopurifier®, a first-in-class device that selectively targets the rapid
elimination of circulating viruses and tumor-secreted exosomes that promote
cancer progression. Exosome Sciences, Inc. is a majority owned subsidiary that
is advancing exosome-based products to diagnose and monitor cancer, infectious
disease and neurological disorders. Additional information can be found on-line
at http://www.aethlonmedical.com/ and connect with
the Company on Twitter, LinkedIn, Facebook and Google+.
Certain
statements herein may be forward-looking and involve risks and uncertainties.
Such forward-looking statements involve assumptions, known and unknown risks,
uncertainties and other factors which may cause the actual results, performance
or achievements of Aethlon Medical, Inc. to be materially different from any
future results, performance, or achievements expressed or implied by the
forward-looking statements. Such potential risks and uncertainties include,
without limitation, that Exosome Sciences, Inc. will not be able to
commercialize its future products, including any that can be described as a
liquid biopsy, that the FDA will not approve the initiation of the Company's
clinical programs or provide market clearance of the company's products, future
human studies whether revenue or non-revenue generating of the Aethlon ADAPT™
system or the Aethlon Hemopurifier® as an adjunct therapy to improve patient
responsiveness to established cancer or hepatitis C therapies or as a
standalone cancer or hepatitis C therapy or as a broad spectrum defense against
viral pathogens, including Ebola, the Company's ability to raise capital when
needed, the Company's ability to complete the development of its planned
products, the Company's ability to manufacture its products either internally
or through outside companies and provide its services, the impact of government
regulations, patent protection on the Company's proprietary technology, the
ability of the Company to meet the milestones contemplated in the DARPA contract,
product liability exposure, uncertainty of market acceptance, competition,
technological change, and other risk factors. In such instances, actual results
could differ materially as a result of a variety of factors, including the
risks associated with the effect of changing economic conditions and other risk
factors detailed in the Company's Securities and Exchange Commission filings.
The Company undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future
events, or otherwise.
Contacts:
Sign up
for the free investor news and stock alerts:
Disclaimer/Disclosure: The Investorideas.com newswire is a third party
publisher of news and research as well as creates original content as a news
source. Original content created by investorideas is protected by copyright
laws other than syndication rights. Investorideas is a news source on Google
news and Linkedintoday plus hundreds of syndication partners. Our site does not
make recommendations for purchases or sale of stocks or products. Nothing on
our sites should be construed as an offer or solicitation to buy or sell products
or securities. All investment involves risk and possible loss of investment.
This site is currently compensated by featured companies, news submissions,
content marketing and online advertising. Contact each company directly for
press release questions. Disclosure is posted on each release if required but
otherwise the news was not compensated for and is published for the sole
interest of our readers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Disclosure:
AEMD subscribes to the Investorideas newswire content publishing annual program
(9700 per Year, paid quarterly) for news publishing.
BC
Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors
should review all OTC and Pink sheet listed companies for adherence in new
disclosure filings and filing appropriate documents with Sedar. Read for more
info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors
must adhere to regulations of each country.
Become an Investorideas.com Member and access our 14 online stock
directories 24/7 –biotech, defense, mining stocks, oil and gas stocks and
more...
